Journal article icon

Journal article

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Abstract:
Background
Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer–BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenic... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/s0140-6736(21)01694-9

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Author
ORCID:
0000-0002-0749-8329

Contributors

Role:
Contributor
Publisher:
Elsevier
Journal:
The Lancet More from this journal
Volume:
398
Issue:
10303
Pages:
856-869
Publication date:
2021-08-06
Acceptance date:
2021-07-20
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Pmid:
34370971
Language:
English
Keywords:
Pubs id:
1190219
Local pid:
pubs:1190219
Deposit date:
2022-01-12

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP